Abstract: Subject matter of the present invention is a combination medication for use in the treatment of a patient having acute and/or persistent dyspnea comprising at least two of the following components: a beta blocker, and one agent of the group consisting of an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II inhibitor and a combination of angiotensin II inhibitor or an angiotensin receptor-neprilysin inhibitor (ARNi), and mineralo receptor antagonist (MRA), gliflozine, a loop-acting diuretic, wherein a sample of bodily fluid of said patient has a level of BNP>200 pg/mL and/or has a level NT-proBNP>600 pg/mL, and wherein said sample of bodily fluid is selected from the group comprising blood, plasma and serum, and wherein said patient is either a patient with heart failure with left ventricular ejection fraction (LVEF) greater and equal to 40%, preferably 50%, or a patient with no heart failure.

Abstract: The present invention relates in particular to the field of anesthesia and to a method for real-time evaluation of the mean arterial pressure of a patient from plethysmography measurements. It also relates to a method for treating a patient comprising by continuously evaluating the mean arterial pressure of the patient, based on values continuously calculated by plethysmography.

Abstract: The present invention relates in particular to the field of anesthesia and to a method for real-time evaluation of the mean arterial pressure of a patient from plethysmography measurements.

Abstract: The present invention concerns the use of CD146 as a marker of the vascular wall tension, especially for diagnosing, predicting and/or prognosticating diseases associated with variations of the vessel wall tension.

Abstract: Novel prognosis methods associated with cases of postpartum haemorrhage providing a predictive test enabling practitioners to provide better management of patients suffering from postpartum haemorrhage. Different risk factors exist on which a score allowing prediction of the need to carry out invasive procedures to stop bleeding has been developed.

Abstract: The present invention relates to an in vitro method of prognosis for the arrest of bleeding in a patient suffering from postpartum haemorrhage in the absence of an invasive procedure, comprising the following steps: (a) determining, using a biological sample from said patient, the plasma fibrinogen concentration, the blood troponin concentration and also the prothrombin time; (b) studying at least two clinical markers for said patient, selected from the group comprising heart rate and the presence of placentation abnormalities; (c) calculating a score Z according to the following equation: Z=a+b+v+d+e; where a is associated with the existence of placentation abnormalities in said patient, with a being 0 when no placentation abnormality is observed in said patient and a being 1 when one or more placentation abnormalities are observed in said patient; where b is associated with the heart rate of said patient, with b being 0 when the heart rate of said patient is less than or equal to 115 bpm (beats per minute)